That may be good news for Boston Scientific’s struggling cardiac rhythm management business, which experienced a 10% drop in sales during the company’s 1st quarter.
The 4-Front device, which is not yet cleared by the FDA, features novel coatings designed to enhance the device’s electrical properties and prevent tissue in-growth into defibrillation coils, according to a press release.
The newly launched leads are part of Boston Scientific’s Reliance suite, which have a 98.9% survival probability at 8 years and which have been implanted in 350,000 patients worldwide, according to the company.
"Leveraging the Reliance platform, we made a series of targeted design enhancements with Reliance 4-Front to improve and simplify implantation," BSX cardiac rhythm management group chief medical officer Dr. Kenneth Stein said in prepared remarks. "Reliance 4-Front represents our continued dedication to product innovation to meet the needs of patients and physicians."
The news represents another win for the medical device industry titan, which last week won new public and private insurance reimbursement codes for its Alair asthma treatment device and announced a definitive agreement to purchase vascular devices maker BridgePoint Medical for an undisclosed amount.
BSX shares saw a modest decline today, trading lower by 0.4% at $5.77 as of about 12:10 p.m.